Structured evidence table for Omega-3 Triglyceride Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Omega-3 Triglyceride Randomized Trial | The results showed that CRP levels increased from 9.86 ± 12.64 to 11.46 ± 22.23 mg/L in the intervention group and from 5.24 ± 9.01 to 5.61 ± 7.93 mg/L in the control group (p = 0.11). | 2 | Shafaei Kachaei H (2026) | Modulation of Inflammatory Indices by Omega-3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach. |
| Omega-3 Triglyceride Randomized Trial | Similarly, IL-6 levels increased from 17.84 ± 14.08 to 81.82 ± 66.22 pg/mL in the intervention group and from 14.96 ± 18.41 to 56.73 ± 115.45 pg/mL in the control group (p = 0.53). | 2 | Shafaei Kachaei H (2026) | Modulation of Inflammatory Indices by Omega-3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach. |
| Omega-3 Triglyceride Randomized Trial | ○ Omega-3 fatty acids have anti-inflammatory properties and are reported to be potentially beneficial in reducing inflammation associated with CKD, but the evidence regarding the effectiveness of omega-3 supplements in reducing inflammatory markers in this population remains inconsistent. | 2 | Shafaei Kachaei H (2026) | Modulation of Inflammatory Indices by Omega-3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach. |
| Omega-3 Triglyceride Randomized Trial | This randomized controlled trial aimed to evaluate the effects of omega-3 fatty acids supplementation on inflammatory markers in patients with CKD undergoing hemodialysis. | 2 | Shafaei Kachaei H (2026) | Modulation of Inflammatory Indices by Omega-3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach. |
| Omega-3 Triglyceride Randomized Trial | The updated terminology introduces “metabolic dysfunction-associated steatotic liver disease” (MASLD) to replace NAFLD and “metabolic dysfunction-associated steatohepatitis” (MASH) to replace nonalcoholic steatohepatitis. | 3 | Tamehri Zadeh Seyed Saeed (2026) | Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives |
| Omega-3 Triglyceride Randomized Trial | According to the new criteria, MASLD is diagnosed in individuals who have hepatic steatosis along with at least one of five cardiometabolic risk factors, provided that no other underlying causes for liver fat accumulation are identified (;). | 3 | Tamehri Zadeh Seyed Saeed (2026) | Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives |
| Omega-3 Triglyceride Randomized Trial | MASLD increases the risk of CVD, hypertension, cardiomyopathy, heart arrhythmias, and cardiovascular mortality (). | 3 | Tamehri Zadeh Seyed Saeed (2026) | Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives |
| Omega-3 Triglyceride Randomized Trial | Bae, 2024 Rinella et al., 2023 Multinational liver societies from the U.S., Europe, and other regions have agreed to revise the terminology and definitions of non-alcoholic fatty liver disease (NAFLD). | 3 | Tamehri Zadeh Seyed Saeed (2026) | Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives |
Source documents